Crizotinib yielded a high objective response rate for adult patients with ALK-positive Inflammatory myofibroblastic tumor, and a 100 percent disease control rate
Research reveals that acquired HER2 mutations confer resistance to hormone therapy in ER-positive metastatic breast cancer
Commercially available research kits extend access to Breath Biopsy technology for discovery of VOC biomarkers in early disease detection and precision medicine
To be in with a chance of winning a $500/£400/450€ Amazon voucher, just tell us which new product, instrument or consumable made the most difference to your lab in 2017
Agilent Measurement Suite to provide researchers with greater experimental freedom
Ultrasensitive Simoa technology to advance research into tumor-derived exosomes at the University of Pittsburgh Cancer Institute
Ralph McDade explains the importance of using ultra-sensitive immunoassays from Quanterix
Bonnie Howell, Executive Director at Merck, discusses the use of ultrasensitive Quanterix technology to develop novel therapies for HIV and shares her hopes for a future world, free of the disease
Henrik Zetterberg discusses the use of ultrasensitive biomarker assays from Quanterix for Alzheimer’s research
Which new product, instrument or consumable has made the most difference to your lab? Nominate now for a chance to win a $500 Amazon voucher
Comprehensive immune profiling & monitoring
Study demonstrates that the test can add prognostic information on overall survival
Mathematical models are used to analyse lymph node morphology and predict risk of cancer spread
Watch our exclusive interviews from industry experts at the Neuroscience 2017 conference
From cancer cells to ocean microbes to Zika virus: Read the interviews that made the most impact in 2017
Discover a new rapid, efficient and reproducible solution for a traditionally complicated method: released N-glycan profiling.
Discover the latest releases, the hottest topics and the stand-out products of the 47th annual society for neuroscience meeting
New biomarker evaluates the biologic activity of blockbuster breast cancer drug Ibrance
Trial will analyze breath biomarkers to improve understanding of the treatment effects of a novel GSK pipeline drug candidate for COPD
